5 GLP-1 Programs That Actually Give You Dosing Flexibility Without Hiding the Price

Something shifted in 2026. After a wave of FDA warning letters and a settlement that pushed several big telehealth brands off compounded semaglutide entirely, a lot of patients suddenly found their programs gone, their doses frozen, or their costs doubled overnight. The ones who came out fine tended to be enrolled somewhere that had built real flexibility into its structure from the start, not just a slick app stapled to a single branded prescription.

What follows is a short, opinionated list of programs where GLP-1 flexible dosing is a genuine feature of the model, not a marketing line. Not every name here is for every person. But each one earns its spot.

1. FormBlends

The thing that sets FormBlends apart is not any single product. It is the combination of scope and accountability you almost never see in one place. A licensed physician reviews your intake, signs off on a prescription, and the medication ships from a compounding pharmacy that operates under 503A rules with cGMP standards and FDA inspection behind it. That is the baseline. Here is what makes it interesting.

The catalog runs from compounded semaglutide at $299 per vial and tirzepatide at $349 per vial all the way through growth hormone peptides, cognitive peptides, and recovery compounds. Every one of those prices sits on the page before you create an account. No membership layered underneath, no “starting at” bait-and-switch. That matters for dosing flexibility specifically because you can move between peptides and GLP-1 agents without switching platforms, losing your prescriber relationship, or getting repriced in the process.

The purity data is public by product. Each batch goes through HPLC to confirm purity, mass spectrometry to confirm identity, and endotoxin testing to confirm sterility. The semaglutide purity figure published is 99.1 percent; tirzepatide sits at 99.3. Those numbers are findable without a login.

FormBlends ships to 47 states, with cold-chain packaging included at no added charge.

One important note: compounded drugs are not FDA-approved finished products. If you want branded Wegovy or Zepbound specifically, you will need a different route.

2. Mochi Health

Mochi built its program around obesity-medicine board-certified specialists rather than general telehealth clinicians, and that choice shows in how dosing conversations actually go. Most GLP-1 platforms give you a set titration schedule and move on. Mochi’s specialists are more likely to slow the ramp based on tolerance, adjust timing, or switch agents if the first one is not working.

Compounded semaglutide runs about $99 per month. Compounded tirzepatide is around $199. Three- and twelve-month commitments bring those numbers down further. The program also accepts insurance for branded meds, which matters if your coverage has changed.

The clinical monitoring is meaningfully heavier than lighter-touch competitors. That is not always convenient, but if you are titrating carefully over six-plus months, it is the kind of structure that actually supports dose adjustments instead of just permitting them.

3. Hims and Hers

Hims and Hers exited compounded GLP-1s in early 2026 after the Novo Nordisk settlement. New patients now access branded medications, which actually opens up a different kind of flexibility: the flexibility of a commercially manufactured product with a full prescribing label, an established titration schedule, and savings-card pricing that can drop branded Wegovy to as low as $0 to $25 per month with commercial insurance.

Without insurance, injectable Wegovy is around $299 per month through the platform. Oral Wegovy runs about $249. Zepbound sits near $399.

The onboarding is fast. The app is genuinely polished. If you want a straightforward branded GLP-1 experience with insurance navigation included, this is one of the smoothest executions in the space. Do not expect peptide add-ons or aggressive compounding-based titration options. That is not what this platform is.

4. MEDVi

MEDVi is the one on this list most people have not heard of yet. No contracts. No recurring membership fee stacked on top of the medication price. First-month compounded GLP-1 programs run around $179, and a physician reviews your case before anything ships. A 24/7 support line is included, which sounds like boilerplate until you are three weeks into your first dose and have a question at 10pm.

The dosing flexibility here comes from a simple structural fact: because there is no annual commitment locking you in, you can pause, adjust, or stop without forfeiting a prepaid plan. That kind of exit flexibility changes how much pressure you feel to push through a dose level that is not working for you, which in turn tends to produce better actual outcomes.

MEDVi is not the fanciest option on this list. But clean, contract-free, and accessible is a legitimate form of flexibility.

5. PlushCare

PlushCare prescribes FDA-approved branded GLP-1 medications, full stop. Ozempic, Wegovy, Mounjaro. The platform membership is about $19.99 per month. Visits, labs, and the prescriptions themselves are billed separately, which means the cost model is unusually transparent compared to programs that bundle everything and obscure what you are actually paying for each component.

Same-day appointments are genuinely available. The platform accepts insurance. If your situation is “I want a licensed clinician to prescribe a named FDA-approved drug, I have insurance, and I want this done today,” PlushCare executes that well.

Dosing flexibility here is not about compounding or catalog breadth. It is about access speed and prescriber responsiveness. For some patients, that is exactly the bottleneck.

A Few Things Worth Saying Before You Decide

Compounded GLP-1 medications are not FDA-approved finished drug products. Branded medications carry full FDA-reviewed labeling; compounded ones do not. Neither category is without tradeoff. The right answer depends on your insurance status, your health history, your budget, and what your own clinician thinks about your specific situation. Before adjusting any dose or switching any program, running the plan past a qualified healthcare professional is the move, not a formality.

Sources

• FDA (fda.gov): compounding pharmacy regulations, 503A guidance, 2026 warning letters on GLP-1 marketing
• Drugs.com: branded GLP-1 drug information and prescribing details
• GoodRx: current cash and insurance pricing for Wegovy, Zepbound, Ozempic, Mounjaro
• Examine.com: semaglutide, tirzepatide, and peptide research summaries
• Cleveland Clinic: how GLP-1 receptor agonists work and clinical perspectives on weight management
• Verywell Health: telehealth GLP-1 program comparisons
• Healthline: GLP-1 receptor agonist dosing and titration guides
• NEJM (New England Journal of Medicine): SURMOUNT and STEP trial publications on tirzepatide and semaglutide efficacy

[internal: placement #1 | structure: Tight curated list, opinionated picks]